ArticleTurkish journal of medical sciences2025
Discontinuation of hydroxychloroquine due to suspected retinal toxicity in systemic lupus erythematosus and the role of multimodal imaging.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: To evaluate the effect of hydroxychloroquine (HCQ) on disease activity and damage in patients with systemic lupus erythematosus (SLE) in whom HCQ had previously been discontinued due to retinal toxicity, and to examine and reevaluate toxicity findings through a detailed ophthalmological examination. Materials and methods: Patients with SLE who had been on HCQ for at least 3 years after achieving lupus low disease activity state (LLDAS) following remission induction, and were followed up for at least 3 years after HCQ discontinuation due to retinal toxicity diagnosed by visual field testing, were analysed. Disease activity, the number and severity of flares and damage were recorded whilst on HCQ and after cessation. All patients were examined by two ophthalmologists using multimodal imaging techniques to further analyse toxicity. Results: Sixty-one patients (age at diagnosis 33.4 ± 10.5, 88.5% female) were included. The percentage of visits maintaining LLDAS was significantly higher during HCQ treatment (p = 0.001). A significant number of patients experienced flares after HCQ discontinuation, with the mild-moderate type predominating (p = 0.006 and p = 0.026). Mean damage scores were higher at the end of the study period (p = 0.001). In the ophthalmologic examination (mean duration after drug cessation: 70.3 ± 52.3 months), signs of HCQ toxicity were not detected in 40 patients (65.6%), and HCQ was reinitiated for these patients. Of 21 (34.4%) patients who had visual field defects in reexamination, only five (8.2%) had typical retinal toxicity by multimodal imaging. Sixteen (26.2%) patients had macular atrophy due to other causes. Conclusion: Hydroxychloroquine is effective in controlling disease activity and preventing damage in SLE, and the opportunity for remedication is valuable. More than half of the patients who could restart HCQ after reexamination show the importance of performing multimodal imaging to diagnose retinal toxicity and to distinguish macular pathologies with different aetiological background.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.